Bayer AG, Germany-based pharmaceuticals giant, declared on Monday that it would challenge the Indian Intellectual Property Appellate Board’s decision regarding its anti-cancer drug Nexavar in high court. The Controller General of Patents (CGP) allowed Hyderabad-based Natco to produce and sell a generic version of Bayer’s anti-cancer drug Nexavar. The German pharmaceuticals company opposed the decision and took the matter to India’s Intellectual Property Appellate Board (IPAB), which upheld the CGP’s decision. read more
[via Stock Watch - Stock Specific News]
Follow us @enterpriseheat – lists / @sectorheat
Follow us @enterpriseheat - lists / @sectorheat
